Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes
This systematic review and meta-analysis assesses the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in children and adolescents with obesity, prediabetes, or type 2 diabetes.
FATP2 at the crossroads of fatty acid transport, lipotoxicity, and complex disease
Type 2 diabetes mellitus affects over 38 million Americans, with diabetic kidney disease as a major complication partly driven by lipotoxicity. Fatty acid transport protein 2 (FATP2) regulates uptake and activation of long-chain fatty acids, making it a therapeutic target in metabolic disease. In this issue of the JCI, Khan et al. investigated FATP2 in […]
Fatty acid transport protein 2 inhibition enhances glucose tolerance through α cell–mediated GLP-1 secretion
Type 2 diabetes affects more than 38 million people in the United States, and a major complication is kidney disease. During the analysis of lipotoxicity in diabetic kidney disease, global fatty acid transport protein 2 (FATP2) gene deletion was noted to markedly reduce plasma glucose in db/db mice due to sustained insulin secretion. To identify […]
GLP-1 therapies for obesity care
GLP-1 therapies are a class of medicines that help lower blood sugar, support weight loss, reduce the risk of heart and kidney complications, and can even lower the risk of early death in people with type 2 diabetes. These must be prescribed by your health care specialist and require close follow-ups. People living with obesity, […]
WHO issues guidance on GLP-1 drugs for obesity
The World Health Organization issued new guidelines recommending the use of GLP-1 drugs for adults with obesity and called for action on manufacturing and affordability.
Coprescribing GLP-1 Receptor Agonists and Lifestyle
To the Editor The importance of integrating lifestyle modification when initiating glucagon-like peptide-1 and dual receptor agonists (GLP-1 RAs) for type 2 diabetes and/or obesity cannot be overstated. As referral to a registered dietitian or lifestyle medicine specialist is ideal but not always feasible, providing clinicians with practical, evidence-based resources for use when coprescribing GLP-1 […]
Coprescribing GLP-1 Receptor Agonists and Lifestyle—Reply
In Reply We thank Rockwell et al for their letter and the opportunity to clarify the below points about our article.
Madrigal Pharmaceuticals (MDGL) Surged Following the Strong Launch and Execution of New Drug
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities hit a record high in the third quarter, fueled by continued gains in technology and falling bond yields. Easing tariff rhetoric and renewed AI infrastructure investments boosted large tech stocks. […]
WHO recommends GLP-1 drugs for obesity
The World Health Organization on Monday recommended GLP-1 drugs as a tool to manage obesity in adults, marking a shift in the way the U.N. agency has historically framed obesity treatment.
It’s official: Global health body makes historic call on weight-loss drugs
The World Health Organization (WHO) has finally made its recommendations on using glucagon-like peptide-1 (GLP-1) therapeutics for weight loss, though it remains to be seen whether it changes their status for prescribing or their price. Continue Reading Category: Obesity, Illnesses and conditions, Body and Mind Tags: World Health Organization, Obesity, GLP-1 receptor agonists, Semaglutide, Weight […]